Search research articles
Contact Us
Filters
Showing results (21-30 of 35) with videos related to
Page
of 4
Sort By:
Leukemia & Lymphoma
|
March 4, 2024
Sensitivity, specificity, and accuracy of molecular profiling on circulating cell-free DNA in refractory or relapsed multiple myeloma patients, results of MM-EP1 study
C Quivoron, J-M Michot, A Danu, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 22, 2019
Haematological immune-related adverse events with immune checkpoint inhibitors, how to manage?
J M Michot, J Lazarovici, A Tieu, et al.
La Revue De Medecine Interne
|
November 1, 2019
[Immune-related adverse events after immune checkpoints inhibitors in 2019: An update]
T Comont, J Belliere, V Sibaud, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 19, 2017
From hepatitis C virus infection to B-cell lymphoma
L Couronné, E Bachy, S Roulland, et al.
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique
|
May 8, 2023
Incidence, characteristics, management and outcome of patients with follicular lymphoma with tumor epidural compression, a study on 22 cases
A Gueiderikh, M Ung, J Lazarovici, et al.
Cancer Chemotherapy and Pharmacology
|
June 24, 2023
Infections occurring following IL6 blockade for the management of cytokine release syndrome in onco-hematology patients
M Valery, K Saleh, R Ecea, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 6, 2020
Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure: a case report
J-M Michot, L Albiges, N Chaput, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 5, 2021
Bamlanivimab + etesevimab therapy induces SARS-CoV-2 immune escape mutations and secondary clinical deterioration in COVID-19 patients with B-cell malignancies
F Pommeret, J Colomba, C Bigenwald, et al.
International Journal of Antimicrobial Agents
|
May 3, 2014
Very prolonged liposomal amphotericin B use leading to a lysosomal storage disease
J M Michot, C Gubavu, E Fourn, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 11, 2018
Immunotherapy phase I trials in patients Older than 70 years with advanced solid tumours
H Herin, S Aspeslagh, E Castanon, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 35) with videos related to
Sort By:
Page
of 4
Leukemia & Lymphoma
|
March 4, 2024
Sensitivity, specificity, and accuracy of molecular profiling on circulating cell-free DNA in refractory or relapsed multiple myeloma patients, results of MM-EP1 study
C Quivoron, J-M Michot, A Danu, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 22, 2019
Haematological immune-related adverse events with immune checkpoint inhibitors, how to manage?
J M Michot, J Lazarovici, A Tieu, et al.
La Revue De Medecine Interne
|
November 1, 2019
[Immune-related adverse events after immune checkpoints inhibitors in 2019: An update]
T Comont, J Belliere, V Sibaud, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 19, 2017
From hepatitis C virus infection to B-cell lymphoma
L Couronné, E Bachy, S Roulland, et al.
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique
|
May 8, 2023
Incidence, characteristics, management and outcome of patients with follicular lymphoma with tumor epidural compression, a study on 22 cases
A Gueiderikh, M Ung, J Lazarovici, et al.
Cancer Chemotherapy and Pharmacology
|
June 24, 2023
Infections occurring following IL6 blockade for the management of cytokine release syndrome in onco-hematology patients
M Valery, K Saleh, R Ecea, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 6, 2020
Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure: a case report
J-M Michot, L Albiges, N Chaput, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 5, 2021
Bamlanivimab + etesevimab therapy induces SARS-CoV-2 immune escape mutations and secondary clinical deterioration in COVID-19 patients with B-cell malignancies
F Pommeret, J Colomba, C Bigenwald, et al.
International Journal of Antimicrobial Agents
|
May 3, 2014
Very prolonged liposomal amphotericin B use leading to a lysosomal storage disease
J M Michot, C Gubavu, E Fourn, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 11, 2018
Immunotherapy phase I trials in patients Older than 70 years with advanced solid tumours
H Herin, S Aspeslagh, E Castanon, et al.
Page
of 4